The occurrence of decompensation marks a crucial turning point in the course of cirrhosis. The purpose of this study was to assess the risk of mortality according to the clinical characteristics of fi rst decompensation, considering also the impact of acute-on-chronic liver failure (AoCLF).
INTRODUCTION
Th e disease course of cirrhosis, one of the worldwide leading causes of death, is characterized by an initial symptomless period of variable extent ( 1 ) . However, during this chronic process, increasing portal pressure and decreasing liver function over time result in the development of hepatic decompensation that corresponds to a crucial turning point of this condition because it is associated with over 50 % risk of further complications or death within a relatively short period of time ( 2 -4 ) . Th is decompensated stage deeply aff ects both the clinical management and the followup strategies ( 5 -7 ) . Despite the magnitude of the problem, a survey that assessed the outcome of patients with cirrhosis since the onset of decompensation according to its clinical features, namely inception cohort study, is still lacking.
In the attempt to overcome the weaknesses of the available information, D ' Amico et al. ( 8 ) carried out a systematic review. Based on its results, they proposed to categorize cirrhotic patients by a multiple-step classifi cation that identifi es two stages of decompensated cirrhosis according to the characteristics of complications at presentation, and to their diff erent rates of mortality. Nevertheless, the quoted systematic review suff ers from several important methodological fl aws as a consequence of being modeled by data collected retrospectively and obtained from studies carried out in a period when treatment of portal hypertension-related complications was still in its infancy. Furthermore, the suggested stage system ( 8 ) did not distinguish patients at their fi rst decompensation from those who had already experienced it. Moreover, the authors did not consider the clinical impact of the acute deterioration upon a preexisting liver disease (acute-on-chronic liver failure (AoCLF)), the defi nition of which was only recently stated by the Asian Pacifi c Association for the Study of the Liver (APASL) ( 9 ) . Finally, one more interesting issue on this topic, which has never been investigated so far, refers to the prognostic importance and the clinical outcome of ascites detectable only by ultrasonography since its fi rst occurrence.
Th e aim of this prospective nationwide inception cohort study (EPA-SCO) was to evaluate the disease course of cirrhosis since the onset time of the fi rst complication. Th e enrolled patients were allocated in distinct subcohorts according to the diff erent characteristic of decompensation at study entry.
METHODS
Th e EPA-SCO study was carried out on behalf of the Italian Association for the Study of the Liver Disease (AISF).
Study population
Between October 2007 and October 2008, we enrolled all consecutive patients with cirrhosis (either followed by periodically surveillance as outpatients or aft er in-hospital admission) in whom a fi rst episode of liver decompensation defi ned as (i) ascites (overt or ultrasound detected alone (UD), (ii) gastroesophageal variceal bleeding (GEVB), (iii) hepatic encephalopathy (HE), (iv) jaundice, and (v) hepatorenal syndrome (HRS), has occurred. A total of 29 centers scattered throughout Italy agreed to participate.
Th e collection of personal data was made in full compliance with the Italian law on personal data protection, and each patient gave his / her consensus in participating. Inclusion criteria were age >18 years and diagnosis of cirrhosis, whereas all patients with previous episodes of liver decompensation, diagnosis of hepatocellular carcinoma (HCC), HIV co-infection, drug addiction, concomitant extrahepatic neoplasm, hemodialysis, and solid organ or bone marrow transplantation were excluded.
Diagnostic criteria for inclusion
At baseline, demographic, etiologic, and biochemical variables were set up. Diagnosis of previous compensated cirrhosis (either by histology or based on clinical ground) was available in all patients who had undergone periodical follow-up. For those who were unaware of a preexisting liver disease, diagnosis was obtained by the evaluation of clinical certifi cation / record (when available) and / or confi rmed during hospitalization by ultrasound, computed tomography scan, and upper endoscopy. In the latter group of patients, a detailed history of the prior clinical course of their disease was accurately investigated at study entry in order to confi rm the inclusion criteria.
As mentioned above, ascites was diagnosed both by clinical examination (overt ascites) and ultrasonography (UD ascites). Th e detection of UD ascites was systematically looked for and reported, if present, at study entry, and its presence has been confi rmed by two independent physicians. UD ascites was ascertained prospectively in patients previously free of ascites who were on regular surveillance for their liver condition. For the remaining individuals we cannot exclude that UD ascites could have been already present. Diagnostic paracentesis was performed in all patients with overt ascites in order to establish its portal-hypertensive nature by serum-ascites albumin gradient and to assess the concomitant presence of spontaneous bacterial peritonitis (SBP) by a polymorphonuclear cell count in ascitic fl uid >250 cell / mm 3 ( 10 ) . HRS and refractory ascites were diagnosed according to the International Ascites Club criteria ( 11 ) . Bleeding was attributed to the rupture of GEVB by endoscopic report according to Baveno guidelines ( 12 ) . HE was defi ned as an episode of neurological and neuropsychiatric abnormality (drowsiness, mental confusion, and disorientation) revertible aft er an eff ective ammonia-lowering treatment ( 13 ) . Initially, patients were allocated in the above-mentioned subcohort categories. Patients with mixed synchronous complications at presentation (i.e., ascites + GEVB and ascites + HE) were categorized apart. Later, in the beginning of 2010, based on the availability of the AoCLF criteria developed by the consensus recommendations of APASL ( 14 ) , which includes (i) jaundice (serum bilirubin ≥ 5 mg / dl), (ii) coagulopathy (international normalized ratio ≥ 1.5), and (iii) de novo occurrence of ascites and / or encephalopathy, the protocol was amended. Both the preexisting diagnosis of stable compensated cirrhosis and a possible / probable acute hepatic insult within a 4-week period before the onset of the above-mentioned concurrent conditions were carefully required to certify this diagnosis. A detailed report for intake of diff erent drugs or infections over the past 3 months was also taken. Accordingly, all patients who fulfi lled the APASL criteria at the time of study entry were retrospectively post hoc allocated in this category. Hence, in order to follow the results more easily, patients were presented as AoCLF and non-AoCLF subcohorts.
Presence of HCC was assessed by two coincidental imaging techniques ( 15 ) and, in controversial cases, also by a fi ne needle biopsy.
Th e etiology of cirrhosis was based on viral markers (anti-HCV and hepatitis B surface antigen (HBsAg)), amount and duration of alcohol intake, confi rmed by relatives, autoantibodies, markers of iron overload, and criteria of metabolic syndrome for nonalcoholic steatohepatitis (NASH). Cryptogenic cirrhosis was diagnosed in the absence of any viral, autoimmune, or metabolic etiology. Th e Child -Turcotte -Pugh (CTP) classifi cation ( 16 ) , the Model for End-Stage Liver Disease (MELD) ( 17 ) , and the MELDNa ( 18 ) scores were determined at the initial visit. Treatments of complications were carried out according to current guidelines in all centers ( 10 -12 ) . For patients with UD ascites, a low-salt diet was prescribed, and spironolactone was also administered on the basis of the Na + / K + urinary excretion ratio . Patients with GEVB received injection sclerotherapy, endoscopic band ligation, or transjugular intrahepatic portosystemic shunt. All these patients were discharged with β -blocker secondary prophylaxis unless contraindications or subjective intolerance were present.
Schedule of follow-up
Th e follow-up schedules aft er hospital release were pre-established by the writing committee and they were based on 3-month intervals (clinical and biochemical ultrasonography). Th ese schedules were not modifi ed aft er the protocol amendment. However, each center could adapt the visit periodicity individually, as clinically required.
Statistical analysis
Data were collected in a pre-established electronic CRF database (web-based data collection, e-CRF provided by Air-Tel, Airon Telematica, Milan, Italy). Diff erences in the distribution of subject characteristics between groups were evaluated by the analysis of variance and the χ 2 analysis for continuous and categorical variables, respectively. In time-to-event analyses, the considered event of interest was death or orthotopic liver transplantation (OLT). HCC was considered as a competing event. Th e observation started from the time of fi rst episode of decompensation. Data were censored on the date of the last follow-up visit. Th e cumulative incidences of death or OLT and HCC were calculated using the method of Kalbfl eisch and Prentice ( 19 ) and compared across diff erent subgroups using the Gray test ( 20 ) . For multivariate analyses, Cox proportional hazard regression modeling was used to analyze the factors associated with the outcomes and hazard ratios and 95 % confi dence intervals (CIs) were calculated for the strength of association.
A direct comparison of a model that includes only MELD score as a covariate and a model including also the type of decompensation at baseline was carried out. To evaluate the incremental predictive information of the new disease defi nition, we used the likelihood ratio test ( 21 ) . We also assessed the improvement in risk prediction when the covariates age, sex, body mass index, alanine transaminase, hemoglobin, sodium, and presence of diabetes were incorporated into the model.
A P value of < 0.05 was considered statistically signifi cant. All P values were two tailed. Statistical analyses were performed with the SAS soft ware (version 9.3, Cary, NC), and the R soft ware http://www.R-project.org/ .
RESULTS
A total of 569 subjects were enrolled, and 79 were excluded, either because of diagnosis of concurrent HCC or because previously reported episodes of decompensation were found. Th e fl owchart of the study is illustrated in Figure 1 .
Th e clinical and laboratory characteristics of the 490 evaluated patients at inclusion are shown in Table 1 . Approximately two-thirds of patients were men and the mean age was 60.9 years (range: 18 -87 years). Th e mean values of biochemical parameters were consistent with the diagnosis of established cirrhosis. Th e distribution of CTP classes was: 19.4 % class A, 61.0 % class B, and 19.6 % class C. Gastroesophageal varices were present in 218 patients (55 small, 79 medium, and 84 large varices) and, among them, 91 subjects (41.7 % ) took β -blockers (propranolol or nadolol) as a primary prophylaxis of variceal bleeding. Th e most frequent etiological factor was hepatitis C virus (HCV) infection (41.0 % ), followed by alcohol abuse (30.0 % ). Th e coexistence of HCV and alcohol abuse was ascertained in 11.4 % of patients. Out of 244 HCV-positive patients, 82 (33.6 % ) have been previously unsuccessfully treated with α -interferon with or without ribavirin, whereas none of them received antiviral therapy during the study period. Of the patients, 11 % had hepatitis B virus (HBV) -related cirrhosis. Out of 50 HBsAg-positive patients, 10 (20.0 % ) were taking a nucleoside analog therapy at the time of the enrollment into the study. Autoimmunity, iron overload, NASH, and cryptogenic 
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etiologies accounted for the remaining 17.6 % of cases. Before study entry, 178 (36.3 % ) patients had undergone regular surveillance by their referral centers.
AoCLF subcohort at presentation
In all, 59 (12.1 % ) patients fulfi lled the criteria of AoCLF diagnosis. Table 2 ). Among them, only 10 patients (13.4 % ) were found to have gastroesophageal varices. Female gender was much more prevalent in comparison with the previous two subgroups.
Among the remaining 35 patients, mild-to-moderate HE was diagnosed in 20 cases ( Table 2 ). Eight patients had acute cholangitis and isolated portal vein thrombosis was found in 7 subjects.
Overall, the in-hospital mortality rate of this subcohort of patients was 1.2 % .
Follow-up and survival analysis
Th e median follow-up observed in 455 of 490 (92.9 % ) patients (AoCLF and non-AoCLF pooled together) who agreed to be regularly followed aft er hospital discharge was of 33 months (range 1 -48), for a total of 872 person-years of observation. No signifi cant diff erence of baseline characteristics was found between patients who adhered or refused to be followed-up (data not shown). During the time of observation, 125 patients died, 24 received OLT, and 52 developed HCC (overall incidence 23.0 per 100 person-years, HCC incidence 5.96 per 100 person-years). Sixty-fi ve patients lost to follow-up were also included in the survival analysis. For these patients, follow-up was censored at the time of last observation (median follow-up of 12.3 months, range 1 -29) and their clinical features (age, sex, etiology, and type of fi rst decompensation) did not diff er from those patients who were still on follow-up at the end of the study.
Transition to de novo complications by type of hepatic decompensation at presentation in non-AoCLF patients is reported in Supplementary Material online.
Th e cumulative incidence of failure (death or OLT) aft er the fi rst episode of decompensation was 16 % (95 % CI: 13 -20 % ) at 1 year, 28 % (95 % CI: 24 -32 % ) at 2 years, and 37 % (95 % CI: 32 -42 % ) at 3 years. Th e 3-year cumulative incidence of HCC was 13 % (95 % CI: 10 -17 % ; Figure 2 ). Th e 3-year cumulative incidence of failure was 62 % (95 % CI 45 -75 % ) in AoCLF cohort and 34 % (95 % CI 28 -39 % ) in the non-AoCLF cohorts. Th e main causes of death for 125 patients were the following: liver failure ( n = 77), GEVB ( n = 19), sepsis ( n = 12), HRS ( n = 8), and other causes unrelated to liver disease ( n = 9; Table 3 ). Figure 3 shows the curves of cumulative incidence of death / OLT according to the above-mentioned criteria. A signifi cant diff erence of survival across the diff erent subgroups was observed (Gray test, P < 0.0001). Table 3 shows the cumulative incidence of failure (death and OLT) by type of decompensation at baseline.
Among 225 HCV patients with available information, 81 (36.0 % ) have been previously treated with antiviral therapy. Th e two survival curves of treated and untreated subjects were equivalent ( P = 0.9 by log-rank test; data not shown). As for HBV, the number of patients was too low to be reliable. During follow-up, 41 patients continued to be alcohol abusing. Th eir overall survival rate was lower but not features at study entry. At time 0, 46 patients had ascites alone, whereas HE was found in 13 patients. In six cases, the combination of ascites and HE was found. More than two-thirds of patients reported alcohol abuse as main determinant of their liver disease. Precipitating events of AoCLF were: (i) active alcoholism in 40 (5 with coexisting infections from urinary tract, two from lung, 10 without clear acute insult); (ii) drug-induced liver damage in 10 (nonsteroidal anti-infl ammatory drugs in 4, amoxicillinclavulanate in 4, hypericum perforatum and other unidentifi ed herbal drugs in 2); (iii) active bleeding in 4 cases; and (iv) bacterial infections alone in 4 patients. Hepatitis reactivation was found to be the precipitating factor in one case due to HBV. Four patients had renal failure (creatinine > 1.5 mg / dl). No patient underwent mechanical ventilation or renal replacement. A severe hepatic impairment was very frequent: 62.7 % of these subjects belonged to CTP class C and overall median value of MELD was 20. In hospital, the mortality rate was 3.4 % .
Non-AoCLF subcohort at presentation
In Table 1 , the right column shows the principal clinical and laboratory features of 431 patients with non-AoCLF decompensated cirrhosis. In comparison with previous subjects, these patients were signifi cantly older, with less severe liver impairment. Viral infection predominates as etiological factor for cirrhosis.
Th e main features of this population according to the etiology of their liver disease are shown in Supplementary Table S1 online. Patients with HCV-related cirrhosis were the oldest, whereas patients with dual etiology (virus plus alcohol) were the youngest. Patients with HBV infection or alcohol abuse were predominantly men, whereas female gender was highly represented in autoimmune and NASH / cryptogenic diseases. Compared with patients with HCV etiology, subjects with alcohol-related disease showed a more advanced stage of their condition (CTP class C: 19.6 % vs. 11.1 % , P < 0.001; median MELD: 14 vs. 12, P < 0.001). As expected, diabetes was present across all groups of patients, with the highest prevalence in the NASH / cryptogenic group (42.4 % ). Table 2 shows the clinical and laboratory features of 416 nonAoCLF patients according to the type of clinical complication at presentation. In this group of patients, overt ascites was the most common cause of decompensation (246 cases, 59.1 % ). Among them, 8 patients had concomitant mild or moderate HE. In addition, 37 patients (15.0 % ) had leg edema. Sixteen patients (6.5 % ) had SBP 8 (13 of them were discharged from the hospital aft er starting an antibiotic prophylaxis). HRS was diagnosed in only one patient. Gastroesophageal varices were discovered in 77 patients (31.3 % ) with overt ascites. Interestingly, no diff erence in the occurrence of ascites was seen between patients who were receiving or not prophylactic β -blocker treatment for variceal bleeding (77.4 % vs. 81.1, P = 0.5). GEVB alone was observed in 66 (15.9 % ) patients, but in only 1 patient with concomitant moderate HE. GEVB and overt ascites were concomitantly present in 11 patients (3.1 % ; Table 2 ). At hospital admission, 43 patients received sclerotherapy and 30 endoscopic band ligation, whereas in 7 cases vasoactive therapy
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statistically signifi cant ( P = 0.075 by log-rank test; data not shown) in comparison with that of abstinent individuals.
Predictive model for death / OLT
Th e likelihood of the Cox model including only MELD score was − 773 ( Table 4 , model 1). Th e hazard ratio associated with a 5-point increase estimated from model 1 was 1.52 (95 % CI 1.31 -1.76). When the type of decompensation (categorized as AoCLF, overt ascites, GEVB, and UD) was added to model 1, the likelihood increased signifi cantly to − 769 ( Table 4 , model 2; likelihood ratio test P value = 0.021). In model 2, the type of decompensation remained a statistically signifi cant prognostic factor aft er adjusting for MELD score: when compared with GEVB patients, the hazard ratio for AoCLF, overt ascites, and UD patients were, respectively, 2.35 (95 % CI: 1.11 -4.99), 2.05 (95 % CI: 1.11 -3.77), and 1.28 (95 % CI: 0.61 -2.68).
Furthermore, when age, sex, body mass index, alanine transaminase, hemoglobin, sodium, and presence of diabetes were added to the model, the likelihood increased signifi cantly to − 734 ( Table 4 , model 3; likelihood ratio test P value < 0.0001). In addition, from First of all, we wish to emphasize some methodological aspects of our survey. Th e prospective enrollment of consecutive patients starting from their fi rst complication has reduced potential selection bias. Moreover, the participation of both tertiary and peripheral centers have also minimized referral and recruitment biases because of local issues, and the participation of hospitals scattered all over the Country provided a representative picture of patients with cirrhosis in Italy.
At present, HCV is the main etiological cause of cirrhosis in patients. Th is does not surprise, considering both the high prevalence of this infection in Italy ( 22 ) and the unsatisfactory rates of response achieved with current interferon-based treatment regimen. In contrast, the number of patients with HBV infection was much lower, confi rming that this condition has decreased over the past 20 years in our country, mainly because of the national vaccination plan and effi cacy of antiviral therapy. Patients with alcohol-related etiology showed a more severe condition of the disease at presentation, irrespective of their younger age.
Th e observed fi ndings are somewhat diff erent from the results of a study performed during years 1988 -1996, which enrolled 462 cirrhotic patients referring to 23 Italian hospitals for liver decompensation ( 23 ) . In that study, ~ 40 % of decompensated cirrhosis was attributable to alcohol consumption, whereas a little more than half of the subjects were infected by HCV. Th e discrepancy may be attributed to diff erent characteristics of the enrolled patients. As a matter of fact, in the aforementioned study, all subjects were unaware of their condition and received the fi rst diagnosis of cirrhosis at the time of decompensation, whereas in our survey only one-third of subjects were unaware of their illness before decompensation.
this fi nal multivariable model, AoCLF patients and overt ascites patients remained at a signifi cantly higher risk of event compared with GEVB patients.
Because of the low number of patients belonging to the subgroups, overt ascites plus GEVB, HE, portal vein thrombosis, and cholangitis categories were not included in the multivariable analyses.
DISCUSSION
Th e present nationwide inception cohort study illustrates the epidemiology, clinical features, and disease outcome of patients with cirrhosis aft er the onset of their fi rst episode of liver decompensation. Although lack of data from other countries limits the 
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In this study, HCV subjects were signifi cantly older than alcoholics, suggesting that the disease route would be more indolent in this population. Additionally, the fi nding that the coexistence of HCV and alcohol was associated with the youngest age provides solid evidence about the synergistic role of both factors in accelerating the progression of the disease ( 24 -27 ) . Finally, the observation that a relevant proportion of the etiologies of these patients may be attributed to NASH confi rms that this disorder is not infrequently associated with progression to end-stage liver disease ( 28, 29 ) . Th e reliability of our diagnosis of NASH (still lacking a reliable marker) was certifi ed by the fact that the prevalence of diabetes, which is strictly linked to the metabolic syndrome, was signifi cantly higher in this group of subjects.
Th is study fi rst reports prevalence of AoCLF as determinant of fi rst decompensation. By using the criteria proposed by APASL consensus meeting ( 9 ) , which simply included a revisited version of the classical Child score, we found that at least 12 % of the episodes of fi rst complication in cirrhotic patients could be attributable to AoCLF. Th e fact that this information has not been available so far is not surprising, as although AoCLF should be always suspected in patients with cirrhosis showing sudden liver function deterioration, APASL criteria have not been universally accepted and a consensus for the defi nition of this entity has not been reached yet. Th is justifi es the lower in-hospital mortality rate (3.4 % vs. 10.4 % ) observed in our fi ndings when compared with the one recently reported by Katoonizadeh et al. ( 30 ) . Accordingly, despite the fact that APASL criteria to defi ne AoCLF were also used in that study, the included patients were exclusively aff ected by alcohol-related cirrhosis and the proportion of subjects with systemic infl ammatory response that emerged to be a main determinant of short-term mortality in that study was higher.
Th e bigger group of patients with HBV reactivation, concurrently with the more severe disease stage of patients at presentation 7  20  33  2  21  46  60  71  1  25  109  161  230  2  11  43  50  60  13  21  33  2 and / or endoscopic variceal ligation, (ii) use of prophylactic antibiotic and vasoactive therapy, (iii) a collection of prospective cases instead of retrospective cohorts ( 9 ), (iv) exclusive inclusion of patients at their fi rst decompensation in spite of the presence of patients with previous decompensation, and (v) inclusion of patients with concurrent GEVB and ascites in the same subgroup, whereas in our study patients were considered separately. We acknowledge that the results of this survey require an external validation, possibly performed in countries where the prevalence of some risk factors of cirrhosis is diff erent. We also admit that the post hoc allocation of patients with AoCLF, as well as the negligible number of patients with multiorgan failure in this subgroup of subjects, may impair the strength of our study.
In conclusion, according to the APASL criteria, a substantial proportion of fi rst decompensation in patients with cirrhosis in Italy may be attributable to AoCLF, a distinct syndrome that, irrespective of short-term outcome, had a very poor prognosis over a 3-year follow-up period. In addition, as the risk of mortality of patients who developed UD ascites was not negligible, subjects who developed this complication require a careful follow-up. Both prevalence and mortality rates of GEVB were extremely lower in comparison with those previously described in past surveys. Although the underlying liver functional status, as certifi ed by MELD score, gives reason for diverse rates of mortality between the above-mentioned categories, other characteristics of patients, such as older age, sex male, obesity, and presence of diabetes across diff erent types of fi rst decompensation, were independently associated with the 3-year mortality risk in the single individual.
Both practicing specialists and general practitioners may use these results to (i) better categorize the population of cirrhotic patients at the time of their fi rst complication, (ii) identify the subjects with worst prognosis at more urgent need for liver transplant, and (iii) standardize the criteria for including patients in future studies. Health-care systems may utilize these data to update the knowledge of the impact of this disease and to estimate the amount of economic investments that will be required to aff ord this condition.
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We are indebted to Ms Diana Song for her precious collaboration. (median MELD 29 vs. 20, high proportion of both HRS and multiorgan failure), may justify the diff erent rates (63 % vs. 25 % ) of 3-month mortality between our survey and another study carried out by Garg et al. ( 31 ) on 91 patients with APASL-AoCLF. In addition, the low number of multiorgan failure in our study also explains the lack of diff erence observed in in-hospital mortality between AoCLF and decompensated cirrhosis. Regarding this, whether patients with other multiple end-organ failures (as allowed by the EASL-Chronic Liver Failure (CLIF) Consortium Canonic study) should be included in AoCLF defi nition is still a matter of debate ( 32 ) . Nevertheless, while waiting for the attainment of a general agreement, these criteria might be useful if applied in daily practice, as the main innovation that has emerged from our study is that the adoption of APASL criteria for AoCLF enables to infer a prospect of the long-term prognosis at the time of the patient ' s fi rst complication.
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Guarantors
Aft er exclusion of patients with AoCLF, ascites still remained the most frequent complication, and in a not-negligible number of cases it could be identifi ed only by ultrasound examination . To our knowledge, no study has compared the survival rate of patients with UD ascites with that of patients with overt ascites so far. Regrettably, we did not compare a reference population of patients with compensated cirrhosis but we observed that the 3-year mortality rate of patients with UD ascites was approximately eightfold higher than the one reported by other previous investigations in patients with compensated disease ( 33, 34 ) . Th is fi nding, in addition to the rapid progression of overt ascites in approximately one-fi ft h of cases, is relevant from a clinical point of view and consistent with the assumption that UD ascites represents a very early stage of liver decompensation. Meanwhile, whether the practice of a salt-restricted diet and the expanding use of diuretics / albumin could be benefi cial in these patients are matters of dedicated studies.
Survival rates in patients with overt ascites paralleled those reported by Planas et al. ( 35 ) in HCV patients and those described by Alvarez et al. ( 36 ) in alcohol-related cirrhosis. Th e lack of improvement of standard treatments of ascites over the past years, as well as the rapid transition to more severe conditions (refractory ascites, GEVB, SBP, and HRS), indicates that this complication, more accurately than bleeding, refl ects a severe impairment of both circulatory and renal function, giving the justifi cation of the concordance of our results with those obtained in the past ( 37 ) .
Although the prevalence of subjects with concurrent SBP was low, this group of patients showed a signifi cantly lower probability to survive over the fi rst 6 months of follow-up, compared with those with ascites and no SBP. Th e fi nding that the vast majority of these cases received antibiotic prophylaxis according to international recommendations ( 38 ) indicates that the epidemiology of bacterial infections has changed over the years and that the level of effi cacy of the available therapy schedule has lowered ( 39, 40 ) .
In comparison with previous estimates reported by D ' Amico et al. ( 9 ) , we found that both prevalence of GEVB as a fi rst cause of decompensation and mortality rates of patients who have bled were extremely low. Th is discrepancy can be ascribed to several reasons: (i) current widespread use of primary prophylaxis with β -blockers
